Drug intelligence / Profile preview

ARB1002

Development stage: Preclinical
Lead developer: Arbele
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

ARB1002 is an antibody-drug conjugate (ADC) being developed by Arbele for the treatment of CDH17-positive tumors. The drug is in preclinical development and targets cancers that express cadherin-17, a protein associated with tumor growth and metastasis. The ADC utilizes monomethyl auristatin E (MMAE) as its cytotoxic payload, which is delivered specifically to cancer cells expressing CDH17, aiming to improve efficacy while minimizing off-target toxicity[1][4].

Targets

CDH17 (Cadherin-17)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on ARB1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARB1002.

Explore the full profile